Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday

by · The Cerbat Gem

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) is expected to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $5.00 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Contineum Therapeutics Stock Performance

Contineum Therapeutics stock opened at $14.10 on Wednesday. The firm has a market cap of $411.44 million, a price-to-earnings ratio of -6.27 and a beta of 1.07. Contineum Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.33. The firm has a 50 day moving average price of $13.27 and a two-hundred day moving average price of $11.95.

Hedge Funds Weigh In On Contineum Therapeutics

Institutional investors have recently modified their holdings of the company. Strs Ohio acquired a new stake in Contineum Therapeutics in the 1st quarter valued at $27,000. Qube Research & Technologies Ltd bought a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $43,000. Marex Group plc bought a new stake in Contineum Therapeutics during the second quarter valued at $45,000. Bridgeway Capital Management LLC purchased a new stake in Contineum Therapeutics in the second quarter valued at approximately $76,000. Finally, Jane Street Group LLC purchased a new position in shares of Contineum Therapeutics in the 2nd quarter worth about $81,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CTNM. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Royal Bank Of Canada decreased their target price on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research note on Friday, November 21st. Morgan Stanley reissued an “equal weight” rating and issued a $14.00 price target (down from $23.00) on shares of Contineum Therapeutics in a research note on Thursday, January 8th. Robert W. Baird cut their price target on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, November 24th. Finally, Leerink Partners began coverage on shares of Contineum Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $22.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Contineum Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

View Our Latest Stock Analysis on Contineum Therapeutics

Contineum Therapeutics Company Profile

(Get Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

Further Reading